ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1593674
This article is part of the Research TopicEmerging Antimicrobials: Sources, Mechanisms of Action, Spectrum of Activity, Combination Antimicrobial Therapy, and Resistance MechanismsView all 32 articles
Performance Evaluation of Four Antibiotics in BD Phoenix TM NMIC-413 Antimicrobial Susceptibility Testing Panels for Carbapenemresistant Enterobacteriaceae and Carbapenem-resistant Pseudomonas Aeruginosa
Provisionally accepted
- 1Nanfang Hospital, Southern Medical University, Guangzhou, China
- 2珠海市卫生学校, zhuhai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The spread of antimicrobial resistance poses significant threats to human health. In 2024, the WHO classified carbapenem-resistant Enterobacteriaceae (CRE) as a critical-priority pathogen and carbapenem-resistant Pseudomonas aeruginosa (CRPA) as a high-priority pathogen. This study aimed to evaluate the performance of meropenem (MEM), imipenem (IPM), cefepime (FEP), and cefoperazone/sulbactam (SCF) using the BD Phoenix TM NMIC-413 AST panel (NMIC-413 panel) for CRE and CRPA at Nanfang Hospital, China. Methods: A total of 314 archived Gram-negative clinical isolates including 219 Enterobacteriaceae (150 CRE) and 95 P. aeruginosa (56 CRPA) were tested. The NMIC-413 panel and disk diffusion method were used for AST of MEM, IPM, FEP, and SCF. Broth microdilution was used as the reference method. Categorical agreement (CA), essential agreement (EA), very major errors (VME), major errors (ME), and minor errors (MIE) were calculated. Acceptable standards were CA and EA > 90%, ME < 3%, and VME < 1.5%. Results: For CRE, the NMIC-413 panel met acceptable standards, with higher CA values than disk diffusion (99.3%, 96.9%, 98.0%, and 98.7% vs. 98.7%, 96.7%, 96.0%, and 97.3%, respectively). For CRPA, the NMIC-413 panel met acceptable standards, with superior CA values for MEM and FEP than disk diffusion (98.2% and 96.4% vs. 96.4% and 92.9%, respectively), while those for IPM and SCF were similar (98.2% and 92.9% vs. 98.2% and 92.9%, respectively). Conclusion: The NMIC-413 panel demonstrated CLSIcompliant performance for all four tested antibiotics against CRE and CRPA, exhibiting superior reliability compared to conventional disk diffusion methods. Future studies should focus on establishing standardized breakpoints for SCF, expanding the detection spectrum for rare bacterial species, and conducting multicenter validation to assess regional variations. We recommend the NMIC-413 panel for AST of CRE and CRPA isolates as a practical alternative to BMD methods.
Keywords: BD Phoenix TM NMIC-413 panel, cre, CRPA, Antimicrobial susceptibility, Evaluation
Received: 14 Mar 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Guan, Song, Chen, Feng, Fan and Rui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yongyu Rui, Nanfang Hospital, Southern Medical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.